ISSN 1301-143X | E-ISSN 1309-1484
1 İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, İstanbul, Türkiye  
Klimik Dergisi 2010; 23: 35-38
DOI: 10.5152/kd.2010.12
Key Words: Daptomycin, bacteremia, skin infection, endocarditis, Staphylococcus aureus.

Infections due to Gram-positive microorganisms are increasing all over the world. Treatment options in infections caused by resistant Gram-positive bacteria are limited. Daptomycin is the first member of cyclic lipopeptide agents. Its spectrum of activity is the Gram-positive organisms, including resistant species such as methicillin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, vancomycin-resistant S. aureus, and vancomycin-resistant enterococci. Daptomycin has been approved for the treatment of complicated skin and soft tissue infections, S. aureus bacteremia and right-sided infective endocarditis. The recommended dosing regimen is 4-6 mg/kg IV once daily. Dose adjustment is necessary in renal failure. Primary toxicity of daptomycin is reversible dose-related myalgias and weakness.

Key Words
Reviewer's Corner
Author's Corner
Frequently Asked Questions
AVES | Copyright © 2019 Turkish Society of Clinical Microbiology Infectious Diseases | Latest Update: 30.09.2019